AVDL

Avadel Pharmaceuticals plc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website avadel.com
Employees(FY) 41
ISIN nan

Performance

-2.83%

-3.82%

-24.19%

-33.91%

-26.98%

YTD

-23.97%

Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Advanced Technical Analysis

Technical Analysis of AVDL 2024-12-20

The Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 56 suggests a neutral stance, and the overall Technical Score of 33 reinforces the bearish outlook. Collectively, these scores imply a predominantly negative sentiment in the stock, with limited bullish momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AVDL

Stock Rank

Recent News & Updates

2024-12-12 05:06
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock(Simply Wall St.)
2024-12-11 08:00
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy(GlobeNewswire)
2024-12-10 19:00
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy(Globenewswire)
2024-11-19 11:05
UBS Adjusts Price Target on Avadel Pharmaceuticals to $22 From $25, Maintains Buy Rating(MT Newswires)
2024-11-14 05:16
Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
2024-11-13 08:00
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference(GlobeNewswire)
2024-11-13 02:09
Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ...(GuruFocus.com)
2024-11-12 19:00
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference(Globenewswire)
2024-11-12 07:24
Avadel Pharmaceuticals' Q3 Loss Narrows, Revenue Rises(MT Newswires)
2024-11-12 07:21
Avadel: Q3 Earnings Snapshot(Associated Press Finance)
2024-11-12 07:00
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results(GlobeNewswire)
2024-11-11 18:00
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-11-11 07:10
Avadel Pharmaceuticals PLC (AVDL) Q3 2024: Everything You Need To Know Ahead Of Earnings(GuruFocus.com)
2024-11-04 08:00
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12(GlobeNewswire)
2024-11-03 19:00
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12(Globenewswire)
2024-11-01 11:41
US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle(Pharmaceutical Technology)
2024-11-01 08:05
Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term(Simply Wall St.)
2024-10-31 07:00
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation(GlobeNewswire)
2024-10-30 19:00
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation(Globenewswire)
2024-10-24 08:00
Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances(GlobeNewswire)
2024-10-23 20:00
Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances(Globenewswire)
2024-10-18 16:34
Avadel wins FDA approval for narcolepsy drug Lumryz in children(Pharmaceutical Technology)
2024-10-18 09:38
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz(Zacks)
2024-10-17 10:24
Avadel Pharmaceuticals Gets FDA Approval for Lumryz to Treat Cataplexy in Narcolepsy Patients(MT Newswires)
2024-10-17 09:41
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy(GlobeNewswire)
2024-10-16 21:41
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy(Globenewswire)
2024-10-09 17:36
Avadel Pharmaceuticals PLC (AVDL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...(GuruFocus.com)
2024-09-25 08:00
Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent(GlobeNewswire)
2024-09-03 08:00
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)(GlobeNewswire)
2024-09-02 20:00
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)(Globenewswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.